Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of GX-188E therapeutic HPV vaccine in CIN3
KCT0001585Phase 2Recruiting
- Sponsor
- Genexine
- Start
- May 2014
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tirvalimogene teraplasmid in cervical intraepithelial neoplasia (CIN), human papillomavirus infection, Carcinoma In Situ Of Cervix (CIS), sponsored by Genexine. Started May 2014; status: recruiting.
02
Drugs
tirvalimogene teraplasmid
03
Conditions
cervical intraepithelial neoplasia (CIN)human papillomavirus infectionCarcinoma In Situ Of Cervix (CIS)
Beyond the preview
Go deeper on KCT0001585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001585.